Clene Inc. (NASDAQ:CLNN – Get Free Report) insider Mark Mortenson acquired 20,512 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $4.75 per share, with a total value of $97,432.00. Following the completion of the acquisition, the insider now directly owns 28,949 shares of the company’s stock, valued at approximately $137,507.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Clene Stock Performance
Shares of Clene stock traded up $0.01 during trading hours on Tuesday, hitting $4.60. 55,205 shares of the company were exchanged, compared to its average volume of 72,016. The business has a 50-day moving average of $5.16 and a 200-day moving average of $6.53. Clene Inc. has a 1 year low of $3.82 and a 1 year high of $13.20. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $29.76 million, a price-to-earnings ratio of -0.50 and a beta of 0.49.
Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.60) by $0.54. Clene had a negative net margin of 6,890.50% and a negative return on equity of 315.97%. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, analysts expect that Clene Inc. will post -5.26 EPS for the current fiscal year.
Institutional Investors Weigh In On Clene
Wall Street Analyst Weigh In
Several research firms recently commented on CLNN. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Clene in a research report on Monday, September 16th. EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $94.00 price target on shares of Clene in a report on Tuesday, August 6th.
View Our Latest Analysis on CLNN
Clene Company Profile
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
See Also
- Five stocks we like better than Clene
- How to Effectively Use the MarketBeat Ratings Screener
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Stocks to Consider Buying in October
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 5 discounted opportunities for dividend growth investors
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.